Related Stories on Zaltrap
|Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug|
Last week, pharmaceutical companies Sanofi and Regeneron Pharmaceuticals Inc., the manufacturers of the colorectal cancer drug Zaltrap (ziv-aflibercept), said they would cut the drug’s “list price” by 50 percent, in effect extending discounts to purchasers.
Soon after Zaltrap’s August launch into the U.S. market, its price triggered an unprecedented act of defiance on the part of U.S. oncologists: doctors from Memorial Sloan-Kettering Cancer Center wrote in a New York Times editorial that they wouldn’t prescribe the drug because it costs twice as much as Genentech’s Avastin (bevacizumab), a competing drug with similar expected outcomes.
|Zaltrap Price Cut In Half Effective Immediately|
Responding to criticism from oncologists, the French pharmaceutical company Sanofi said that it would cut in half the price of its colorectal cancer drug Zaltrap (ziv-aflibercept).
Critics said Zaltrap’s price—about $11,000 a month—was more than double that of a competing therapy, Genentech’s Avastin (bevacizumab), which is also used in the second-line colon cancer indication.
|Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing|
The colon cancer drug Zaltrap, jointly marketed by Sanofi and Regeneron Pharmaceuticals Inc., is getting the attention no company wants.
It has triggered a discussion about the pricing of cancer drugs. Not the cost—an issue that is explosive enough—but something far deeper: the decisions that go into setting the drug’s price.
|Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer|
Sanofi officials said that, criticism notwithstanding, their drug Zaltrap was priced responsibly and is consistent with other drugs used to treat secondline metastatic colorectal cancer.
Recently, officials at Memorial Sloan-Kettering Cancer Center excluded Zaltrap (ziv-aflibercept) from their formulary because it’s priced twice as high as a comparable agent, Genentech’s Avastin (bevacizumab), but Sanofi officials disputed this analysis.